Bio Pharma Dive
JULY 2, 2025
Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.
Rethinking Clinical Trials
JULY 2, 2025
Although the need for pragmatic research in primary care settings is great, conduct of pragmatic clinical trials in these settings remains nascent. In a session at the NIH Pragmatic Trials Collaboratory’s 2025 Annual Steering Committee Meeting, Wendy Weber of the National Center for Complementary and Integrative Health (NCCIH) led a discussion about how to expand pragmatic research into primary care settings.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JULY 2, 2025
Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.
Scienmag
JULY 2, 2025
Brain tumors exhibit distinct growth behaviors that significantly influence patient outcomes and treatment approaches. Fundamentally, these tumors adopt one of two aggressive strategies to expand within the confined space of the skull: they either exert mechanical pressure by pushing against the surrounding brain tissue or infiltrate by sending invasive, finger-like projections that destroy neighboring neural structures.
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.
The Pharma Data
JULY 2, 2025
argenx Advances ARGX-119 into Registrational Study for Congenital Myasthenic Syndromes Following Positive Phase 1b Data argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving outcomes for patients with severe autoimmune diseases, has announced plans to progress its investigational therapy ARGX-119 into a registrational clinical trial for congenital myasthenic syndromes (CMS).
Scienmag
JULY 2, 2025
In a groundbreaking study published in BMC Psychiatry , researchers explore the nuanced effects of ultra-brief pulse electroconvulsive therapy (ECT) on postoperative delirium in patients diagnosed with schizophrenia (SCZ). This investigation offers vital insights into how ultra-brief pulse (UBP) ECT compares to traditional brief pulse (BP) ECT in minimizing the cognitive side effects commonly associated with this psychiatric treatment.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Scienmag
JULY 2, 2025
In a groundbreaking multicenter study poised to reshape breast cancer treatment strategies, researchers have unveiled new insights into the capabilities of [18F]FLT PET/CT imaging in predicting tumor response to neoadjuvant chemotherapy (NAC). This retrospective analysis leverages a rich dataset from the ACRIN 6688 observational trial, offering a comprehensive examination of how the tumor to background parenchymal ratio (TBR) of standardized uptake values (SUV) can provide critical prognostic in
Pharma Times
JULY 2, 2025
Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Neumifil shows promise in treating influenza with positive phase 2 dat by John Pinching | 2nd Jul 2025 | News Pneumagen’s intranasal antiviral demonstrates reduced infection Pneumagen has announced the publication of phase 2 data showing its antiviral therapy, Neumifil, significantly reduced influenza infecti
Scienmag
JULY 2, 2025
A groundbreaking study from China is reshaping the landscape of lung cancer screening, unveiling a novel predictive model that enhances the accuracy of malignancy assessments for pulmonary nodules detected via low-dose computed tomography (LDCT). Published in BMC Cancer , this research addresses crucial challenges inherent in lung cancer early detection programs, particularly the high rates of false positives and overdiagnosis that undermine the potential life-saving benefits of LDCT screening.
pharmaphorum
JULY 2, 2025
Finland's GlucoModicum thinks it is in the lead in the race to bring a non-invasive continuous glucose monitor (CGM) to market.
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Scienmag
JULY 2, 2025
In recent years, the scientific community and regulatory bodies across the European Union have been grappling with a significant challenge: how to effectively identify endocrine-disrupting substances (EDS) while minimizing the reliance on animal testing. Endocrine disruptors, compounds that interfere with hormone systems, pose substantial risks to human health, wildlife, and ecosystems by contributing to conditions such as cancers, reproductive dysfunctions, and developmental disorders.
pharmaphorum
JULY 2, 2025
The UK has revealed a new 'innovator passport' designed to accelerate the rollout of proven medtech in the NHS.
Scienmag
JULY 2, 2025
In a groundbreaking study published recently in Nature Communications , researchers have unveiled a crucial molecular mechanism by which skeletal muscle adapts to chronic exercise in a time-dependent manner. The team led by Liu, Xiao, and Choubey discovered that the nuclear receptor Rev-erbα, a pivotal component of the cellular circadian clock, orchestrates muscle’s physiological remodeling in response to prolonged exercise regimens in mice.
Velocity Clinical Research
JULY 2, 2025
Very few physicians begin their careers with an eye on research. Moving into the role of Principal Investigator (PI) can be unexpectedly challenging, with demands that often take physicians by surprise. “Much of my experience with clinical research centered around reviewing journal articles for clinical practice,” explains Daniel Williams, DO, FAAEM , who transitioned from emergency medicine into clinical research.
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
Scienmag
JULY 2, 2025
In the intricate world of cellular biology, the organization within a cell is far from random. Much like a finely tuned, multi-compartmentalized factory, cells have distinct regions where specific tasks are performed with remarkable precision. These compartments can be broadly divided into two categories: membrane-bound organelles, such as mitochondria that generate energy and the nucleus that safeguards our genetic blueprint, and membrane-less structures known as biomolecular condensates.
The Pharma Data
JULY 2, 2025
Asahi Kasei Pharma Initiates Phase III Clinical Trial of ART-123 to Combat Chemotherapy-Induced Peripheral Neuropathy Asahi Kasei Pharma Corporation has officially commenced drug administration in a pivotal Phase III clinical trial of ART-123, a recombinant human thrombomodulin (rTM), in Japan. Marketed domestically under the brand name Recomodulin™ Injection, ART-123 is being investigated for its potential to prevent chemotherapy-induced peripheral neuropathy (CIPN)—a debilitating side effect c
Scienmag
JULY 2, 2025
A groundbreaking new study led by researchers at McGill and Concordia universities has unveiled compelling evidence linking women’s subjective perceptions of their social status to early indicators of cardiac stress, potentially setting the stage for future heart disease. This research sheds light on a critical, yet understudied, dimension of cardiovascular risk—how social and psychological factors uniquely influence women’s heart health, underscoring the necessity for a paradigmatic shift in ca
The Pharma Data
JULY 2, 2025
FDA Grants Accelerated Approval to Regeneron’s Lynozyfic™ (linvoseltamab-gcpt) for Relapsed or Refractory Multiple Myeloma Regeneron Pharmaceuticals has secured a critical milestone in oncology drug development with the U.S. Food and Drug Administration’s (FDA) accelerated approval of Lynozyfic™ (linvoseltamab-gcpt), a first-in-class BCMAxCD3 bispecific antibody, for the treatment of adults with relapsed or refractory (R/R) multiple myeloma (MM).
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
Bio Pharma Dive
JULY 2, 2025
Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.
The Pharma Data
JULY 2, 2025
WuXi Biologics Launches WuXiHigh™ 2.0 to Advance High-Concentration Biologic Formulations WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the official launch of WuXiHigh™ 2.0 , a next-generation, high-throughput formulation development platform specifically engineered for high-concentration biologics.
pharmaphorum
JULY 2, 2025
Shionogi has added to its antibiotics pipeline by taking an option on a preclinical-stage candidate from BioVersys for non-tuberculous mycobacteria.
Pharmaceutical Technology
JULY 2, 2025
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
FDA Law
JULY 2, 2025
By Charles D. Snow — Since the U.S. Food and Drug Administration (FDA) launched the Over-the-Counter Monograph User Fee Program (OMUFA) in 2020, the Agency has been pushing for modernization and self-funding of its regulatory oversight for over-the-counter (OTC) products. But five years in, the Agency’s OMUFA Facility Arrears List paints a concerning picture: nearly 1,400 businesses—foreign and domestic—appear to have either ignored or fallen behind on their facility registration payments.
NY Times
JULY 2, 2025
His method of producing the drug Taxol, now used widely to treat various cancers, eliminated the need to source its active compound from endangered trees.
The Pharma Data
JULY 2, 2025
Biogen Launches Global Phase 3 PROMINENT Trial Evaluating Felzartamab in Primary Membranous Nephropathy Biogen Inc. (Nasdaq: BIIB) has announced the initiation of dosing in its global Phase 3 clinical trial, known as PROMINENT, to assess the safety and efficacy of its investigational anti-CD38 antibody, felzartamab , in adults with primary membranous nephropathy (PMN).
Pharmaceutical Technology
JULY 2, 2025
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The Pharma Data
JULY 2, 2025
FDA Grants Priority Review to Merck’s WINREVAIR™ Based on Landmark ZENITH Trial Showing Dramatic Reduction in Morbidity and Mortality in PAH Patients Merck (NYSE: MRK), operating as MSD outside the U.S. and Canada, has announced a significant regulatory milestone for its pulmonary arterial hypertension (PAH) treatment, WINREVAIR™ (sotatercept-csrk).
STAT News
JULY 2, 2025
Flanked by her friends as lawmakers debated the future of a 60-year-old health care plan, Latoya Maddox raised her voice, shouting, “No cuts to Medicaid! No cuts to Medicaid!” The chanting, during a meeting of the House Energy and Commerce Committee on May 13, quickly earned her and her fellow disabled activists in the room a rough escort out by Capitol Police.
The Pharma Data
JULY 2, 2025
As mpox cases surge once again in parts of Central Africa, the Democratic Republic of the Congo (DRC) is leading a bold, innovative strategy by integrating HIV and syphilis testing into its national mpox management framework. This approach, supported by the World Health Organization (WHO), represents a crucial advancement in public health aimed at addressing overlapping vulnerabilities and improving patient outcomes.
Pharma Marketing Network
JULY 2, 2025
In the digital-first era, social media marketing strategies are reshaping how pharmaceutical companies engage with healthcare professionals, patients, and caregivers. These strategies are no longer optional; they are essential. From awareness campaigns to real-time engagement, pharma brands that embrace digital transformation are seeing meaningful results across platforms.
Expert insights. Personalized for you.
242 
Let's personalize your content